Comparison
Cagrilintide vs. CagriSema
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
1415456-99-3
no data
Molecular weight
4253.7 g/mol
no data
Half-life
168 h
no data
Sequence
KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTYno data
Mechanism of action
Cagrilintide
Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
1
of which in humans
3
1
Effects recorded
3
2
Open conflicts
1
0
Documented adverse events
1
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Cagrilintide and CagriSema?
- Cagrilintide is classified as "Metabolic", while CagriSema is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Cagrilintide or CagriSema?
- The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for CagriSema. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Cagrilintide and CagriSema in Germany and the United States?
- Germany: Cagrilintide — Unapproved, CagriSema — Unapproved. United States: Cagrilintide — Unapproved, CagriSema — Unapproved. These are factual summaries with source and review date on the individual pages.